推荐同事 机构合作 中文 繁體中文 English 한국어 日本語 Português Español

美国ACCDON公司旗下品牌

021-33361733，021-33632861

chinasupport@letpub.com

登录 注册 新注册优惠

A Phase II study of interferon alpha (IFN) and intermittent oral cytarabine (YNK01) in the treatment of newly diagnosed chronic myeloid leukemia (CML)

P Mollee, K Taylor, C Arthur… - 2nd Annual Scientific …, 2011 - espace.library.uq.edu.au
Mollee, P., Taylor, K., Arthur, C., Wright, S. and Morton, J. (2000). A phase II study of interferon
alpha (IFN) and intermittent oral cytarabine (YNK01) in the treatment of newly diagnosed chronic
myeloid leukemia (CML). In: , Blood: The 2nd Annual Scientific Meeting of the ...
Cited by 6 - Related articles - Cached

Phase I Pharmacokinetic and Pharmacodynamic Study of the Multikinase Inhibitor Sorafenib in Combination With Clofarabine and Cytarabine in Pediatric Relapsed/ …

[HTML] from ascopubs.orgH Inaba, JE Rubnitz, E Coustan-Smith… - Journal of Clinical …, 2011 - jco.ascopubs.org
Corresponding author: Hiroto Inaba, MD, PhD, Department of Oncology, St Jude Children's Research
Hospital, 262 Danny Thomas Place, Memphis, TN 38105; e-mail: hiroto.inaba{at}stjude.org. ...
Presented in part at the 52nd Annual Meeting of the American Society of Hematology, ...

Lower Cytarabine Doses Effective and Less Toxic in AML Patients

R Nelson - N Engl J Med, 2011 - medscape.com
March 16, 2011 — High doses of cytarabine are more effective than conventional doses in inducing
relapse-free survival in patients with acute myeloid leukemia (AML). Now, data suggest that an
intermediate dose might be just as effective as a high dose, but with less toxicity.

Clinical Relevance of the Dose of Cytarabine in the Upfront Treatment of Primary CNS Lymphomas with Methotrexate-Cytarabine Combination

AJM Ferreri, G Licata, M Foppoli, G Corazzelli… - The …, 2011 - AlphaMed Press
Abstract Background. The combination of high doses of methotrexate (MTX) and cytarabine
(araC) is the standard chemotherapy for patients with primary CNS lymphoma (PCNSL). The
addition of an alkylating agent could improve MTX-araC efficacy because it is active ...
Cited by 1 - Related articles - All 3 versions

Phase I and pharmacological study of cytarabine and tanespimycin in relapsed and refractory acute leukemia

[PDF] from haematologica-thj.orgSH Kaufmann, J Karp, M Litzow, R Mesa… - …, 2011 - haematologica.org
Publisher's Disclaimer. E-publishing ahead of print is increasingly important for the rapid dissemination
of science. Haematologica is, therefore, E-publishing PDF files of an early version of manuscripts
that have completed a regular peer review and have been accepted for publication. E- ...

联系我们 | 站点地图 | 友情链接 | 授权代理商 | 加入我们

© 2010-2024 中国: LetPub上海分公司    网站备案号：沪ICP备10217908号-1    沪公网安备号：31010402006960

增值电信业务经营许可证：沪B2-20211595

礼翰商务信息咨询（上海）有限公司      办公地址：上海市徐汇区漕溪北路88号圣爱大厦1803室

United States: Tel: 1-781-202-9968 Address: 400 5th Ave, Suite 530, Waltham, Massachusetts 02451